174 results about "PEGylation" patented technology

The disclosure provides method of treating cancer in a patient with ATM-deficient or ATR-deficient tumors, comprising safely and efficaciously administering to the patient PLXO38, a long lasting-PEGylated prodrug of the topoisomerase I inhibitor. The disclosure further provides combination therapies of PLXO38 with inhibitors of the DNA damage response (DDR).

The present invention provides synthetic peptide compounds and uses thereof for therapy and diagnostics of complement-mediated diseases, such as inflammatory diseases, autoimmune diseases, and microbial and bacterial infections; and non-complement-mediated diseases, such cystic fibrosis and various acute diseases. The invention is directed to modifications of a synthetic peptide of 15 amino acids from the Polar Assortant (PA) peptide, which is a scrambled peptide derived from human Astrovirus protein. In some embodiments, the invention is directed to peptide compounds that are peptide mimetics, peptide analogs and / or synthetic derivatives of PA (e.g., sarcosine derivatives) having, for example, internal peptide substitutions, and modifications, including PEGylation at the N-terminus and C-terminus. The invention further provides methods of selecting at least one synthetic peptide for treating various conditions.

The invention belongs to the field of biological medicine, and particularly relates to lipid nanoparticles, application thereof and a drug delivery carrier. The lipid nanoparticle comprises an ionizable lipid, cholesterol, phospholipid, a pegylated lipid and a sterol substitute, and is characterized in that the ionizable lipid is Lipid 5, the phospholipid is DSPC, the pegylated lipid is 18: 0 mPEG2000 PE, and the sterol substitute is one or more of beta-sitosterol, stigmasterol or stigmasterol or a derivative thereof; the molar ratio of the ionizable lipid to the cholesterol to the phospholipid to the pegylated lipid to the sterol substitute is (40-60): (5-38.5): (5-30): (1-2): (5-38.5). According to the invention, the LNP with unique physicochemical properties is constructed through high synergy of the components, the technical problems of low delivery efficiency and poor specificity of hematopoietic stem progenitor cells in the prior art are solved, and high-efficiency and high-specificity drug delivery of HSPCs in vivo and in vitro is realized. The invention also provides a drug delivery carrier containing the lipid nanoparticles and a preparation method thereof.

A method and kit are provided for detecting anti-drug antibodies (ADAs) against self-assembling trimeric biologics, such as XPro1595, a pegylated variant of soluble human Tumor Necrosis Factor, in biological samples, particularly human serum. The method employs an Affinity Capture Elution-Protein A / G (ACE-AG) assay that overcomes non-specific reagent interactions inherent in conventional bridging and standard ACE assays due to the biologic's dynamic monomer exchange. The assay utilizes a two-plate system: a streptavidin-coated plate with biotinylated trimeric biologic captures ADAs, which are eluted, neutralized, and transferred to a protein A / G-coated plate for specific immunoglobulin capture and detection with a sulfo-tagged trimeric biologic via electrochemiluminescence. The kit includes pre-coated plates, labeled biologics, elution and neutralization solutions, assay buffer, confirmatory reagent, and instructions. The assay offers a robust, specific, and sensitive solution for immunogenicity testing of trimeric biologics.

The invention discloses a preparation method of a pegylation acoustic catalysis effect black phosphorus loaded biological enzyme nano particle, which is a novel nano composite material based on material chemistry and pharmaceutical chemistry, and bacterial keratitis is treated by using the unique acoustic catalysis property of the nano particle. Nanoparticle synthesis mainly comprises the following steps: 1) pretreatment of commercial black phosphorus; (2) uploading biological enzyme iron-curcumin to black phosphorus in situ; and (3) synthesizing hyaluronic acid coupled phospholipid polyethylene glycol (DSPE-coated PEG2000-HA) and modifying the biological enzyme black phosphorus nanoparticles. The finally obtained nano composite material has good biocompatibility, ocular surface adhesion, biological enzyme activity and acoustic catalytic treatment effect on bacterial biofilm infection of eyes.

The invention relates to lipid nanoparticles for fish in-vivo skin gene editing and application of the lipid nanoparticles, and belongs to the technical field of fish gene editing. The lipid nanoparticle for fish in-vivo skin gene editing comprises a gene editing element and a lipid layer, wherein the lipid layer wraps the surface of the gene editing element; the gene editing element is a CRISPR (clustered regularly interspaced short palindromic repeats) / Cas9 (CRISPR associated protein 9) ribonucleoprotein compound or nucleic acid for coding the compound; the lipid nanoparticle carrier comprises ionizable cationic lipid, auxiliary lipid, cholesterol, pegylated lipid and permanent cationic lipid, and the lipid nanoparticle carrier comprises the following components in parts by mole: 15 parts of ionizable cationic lipid, 25-30 parts of auxiliary lipid, 30 parts of cholesterol, 3 parts of pegylated lipid and 7 parts of permanent cationic lipid. The formula is high in pertinence, high in editing efficiency, simple, convenient and safe to operate and wide in application prospect.

This description provides formulations for a pharmaceutical product comprising a PEGylated CBS protein having the amino acid sequence SEQ ID NO: 1. Dosages and dosage regimens are provided for the treatment of homocystinuria in a subject in need. In addition, dosages and dosage regimens are also provided for reducing homocysteine ​​(Hcy) levels or increasing cysteine ​​(Cys) and / or cystathionine (Cth) levels in a subject in need.

The invention discloses an application of pegylated irinotecan in preparation of a medicine for preventing and / or treating triple-negative breast cancer brain metastasis diseases, which is shown by in-vivo imaging observation and lifetime observation of high, medium and low dose groups of pegylated irinotecan with a specific structure. The high-dose group, the medium-dose group and the low-dose group all have a definite anti-tumor effect, bioluminescence signal values are inhibited to different degrees, the lifetime is prolonged, and the lifetime of the high-dose group and the lifetime of the medium-dose group are remarkably longer than that of the NKTR-102 group.

Formulations of gas-filled microvesicles comprising a ligand, which may advantageously be used in methods for separating cells or biological materials. The formulations comprise a phospholipid and a suitable mixture of a pegylated phospholipid and of a pegylated phospholipid comprising a ligand.

Provided herein is an antibody-drug conjugate (ADC) especially a PEGylated mono- or bispecific antibody hydroxyl-bearing drug conjugate prepared with site-specific conjugation to provide homogeneous conjugate with high potency and low toxicity. The disclosure also relates to a method for the preparation of the antibody hydroxyl-bearing drug conjugate, a composition comprising the antibody hydroxyl-bearing drug conjugate, and the use thereof in treating diseases.

This invention relates to the field of biomedical technology, specifically to a polyethylene glycol-modified liposome loaded with dimethylcurcumin and its preparation method. First, cholesterol is reacted with succinic anhydride to obtain cholesterol monosuccinate. Then, the cholesterol monosuccinate is coupled with polyethylene glycol via an ester bond to synthesize polyethylene glycol-cholesterol. Using polyethylene glycol-cholesterol, polyethylene glycol monostearate, and lecithin as the main components, and dimethylcurcumin as the model drug, polyethylene glycol-modified dimethylcurcumin liposomes are prepared using a thin-film hydration method. These liposomes exhibit high encapsulation efficiency. In vitro simulated drug release experiments show that these liposomes can improve the sustained-release effect of dimethylcurcumin. Cytotoxicity experiments also demonstrate that the polyethylene glycol-modified dimethylcurcumin liposomes possess good antitumor activity.

Provided is a method for improving the stability of urate oxidase. The inventors have discovered that combining an active ingredient urate oxidase or chemically modified urate oxidase with a stabilizer xanthine through a non-covalent bond can significantly improve the in vivo and in vitro stability of urate oxidase and chemically modified urate oxidase in the form of a tetramer, thereby effectively improving the stability of urate oxidase.

Provided herein are targeting compounds (e.g., a compound of Formula I, a stereoisomer thereof, a tautomer thereof, and / or a pharmaceutically acceptable salt thereof), lipid nanoparticle (LNP) compositions comprising such targeting compounds and the use thereof. The LNP compositions described herein may further comprise one or more selected from ionizable lipids, PEG-lipids, phospholipids, and structural lipids.

A drug delivery vehicle comprising a vesicle conjugated to one or more targeting groups, wherein the targeting groups comprise an oligosaccharide which is Lewis A or Lewis B or a mimetic thereof, or a pharmaceutically acceptable salt or PEGylated form of the oligosaccharide:wherein R represents the point of attachment to the vesicle.

This invention relates to lipid nanoparticles for in vivo skin gene editing in fish and their applications, belonging to the field of fish gene editing technology. The lipid nanoparticles for in vivo skin gene editing in fish comprise: a gene editing element and a lipid layer, wherein the lipid layer coats the surface of the gene editing element; the gene editing element is a CRISPR / Cas9 ribonucleoprotein complex or a nucleic acid encoding the complex; the lipid nanoparticle carrier comprises ionizable cationic lipids, auxiliary lipids, cholesterol, polyethylene glycol-modified lipids, and permanently cationic lipids, and by molar weight, the proportions are 15 parts ionizable cationic lipids, 25-30 parts auxiliary lipids, 30 parts cholesterol, 3 parts polyethylene glycol-modified lipids, and 7 parts permanently cationic lipids. The formulation of this invention is highly targeted, has high editing efficiency, is simple and safe to operate, and has broad application prospects.

The application provides a reduction-responsive nano delivery system and application thereof in preparation of a drug for treating drug-resistant tumors, and belongs to the pharmaceutical field. The application constructs a reduction-responsive branched copolymer functionalized by pegylation and deoxycholic acid (DA) (referred to as: pegylated branched poly(HPMA-DA)), which can effectively encapsulate small molecule drugs to form a nano delivery system. Experiments prove that the nano delivery system can be taken up by tumor cells, has good tumor targeting, and exhibits excellent anti-tumor effect in tumor xenografts (CDX) derived from non-small cell lung cancer (NSCLC) chemoresistant cell lines and patient-derived xenograft mouse models (PDX). The pegylated branched poly(HPMA-DA) provided by the application has wide application prospect in preparation of a drug carrier, and the nano delivery system provided by the application has wide application prospect in preparation of a drug for treating cancer.

The invention relates to the technical field of cosmetics, in particular to a makeup removal composition, a preparation method thereof and a makeup removal product. The makeup removing composition is prepared from grease, polyhydric alcohol and an emulsifying agent according to the weight ratio of (10 to 20): (0.5 to 10): (2 to 10), the grease comprises one or more of first grease and second grease; the first grease comprises one or more of ether grease, alkane grease and ester grease; the second grease is selected from pegylated alkanoic acid glyceride compounds; the polyol comprises one or more of a first polyol and a second polyol; the first polyhydric alcohol comprises a diol compound; the second polyol comprises an alkyl glyceryl ether compound. The makeup removing composition and the makeup removing product have efficient makeup removing power and also have a water-based refreshing skin feeling.

The invention belongs to the field of biological medicine, and particularly relates to lipid nanoparticles for local drug delivery, a preparation method of the lipid nanoparticles and application of the lipid nanoparticles to preparation of anti-scar drugs. The lipid nanoparticle comprises a lipid carrier and nucleic acid wrapped by the lipid carrier, and the lipid carrier comprises the following components: an ionizable lipid, a permanent cationic lipid, a pegylated lipid, an auxiliary phospholipid and a sterol compound; the molar ratio of the ionizable lipid to the permanent cationic lipid to the pegylated lipid to the auxiliary phospholipid to the sterol compound is (25-45): (5-25): (1-2): (5-15): (35-40). In order to solve the problem of single administration of lipid nanoparticles in the prior art, the lipid nanoparticles are designed to be externally applied and applied for local administration through proportion regulation and control, so that the targeting property is improved, and the administration concentration is increased. Whole-body blood circulation is avoided, and toxic and side effects and off-target performance are reduced. Therefore, the dual purposes of synergism and toxicity reduction are achieved.

The invention relates to lipid nanoparticles containing an adjuvant for mucosal administration and a preparation method of the lipid nanoparticles. The lipid nanoparticles comprise total lipid, an adjuvant and an active ingredient, wherein the total lipid is composed of cationic lipid C12-200, non-cationic phospholipid, cholesterol and a derivative thereof, and pegylated lipid; wherein the adjuvant is selected from at least one of AS03, MF59, monophosphoryl lipid A, miniaturized monophosphoryl lipid A, ophiopogonin D, saponin QS21, QS7, QS17, QS18, CpG oligonucleotide, 2 '3'-ring GMP-AMP, 3 '3'-ring GMP-AMP, alpha GC, Trehalose-6, 6-dibehenate, cholera toxin B subunit and flagellin.

The invention relates to the technical field of skin care, and discloses a sustained-release composition containing azelaic acid composite lipidosome and application of the sustained-release composition in acne treatment and skin repair. Comprising a composite liposome, an encapsulated active component and a dispersion medium, the composite liposome is composed of a lipid bilayer, the lipid bilayer comprises phospholipid, cholesterol and pegylated phospholipid, and the phospholipid is a mixture of hydrogenated soybean phospholipid and dipalmitoyl phosphatidylcholine; the encapsulated active component comprises a fat-soluble component and a water-soluble component; the water-soluble components comprise a hamamelis virginiana leaf water extract and a herba portulacae extract; the dispersion medium is a phosphate buffer solution; by optimizing lipid composition, introducing surface modification and constructing a multi-layer release system, the invention aims to synergistically exert multiple effects of antibiosis, anti-inflammation, cutin regulation, red fading, repair and the like, and provides an efficient, mild and integrated solution for acne and sequelae skin problems thereof.

The invention discloses a skin implant, the skin implant is a freeze-drying agent, the freeze-drying agent is prepared from the following components in parts by weight: 2-15 parts of a PEG-PLA copolymer and 0.05-4.0 parts of hyaluronate, the PEG-PLA copolymer is prepared from a single-terminal hydroxyl polyethylene glycol compound and lactide through a polymerization reaction, and the hyaluronate is prepared from the following components in parts by weight: 1-10 parts of a cross-linking agent, 1-10 parts of a cross-linking agent, 1-10 parts of a cross-linking agent and 1-10 parts of a cross-linking agent. The mass ratio of the single-end hydroxyl polyethylene glycol to the lactide is (2.0-8.5): 1, and the molecular weight of the hyaluronate is 10-100 WDa. The skin implant provided by the invention has an excellent redissolution speed and can be quickly redissolved within 10 minutes, and the quick redissolution characteristic of the freeze-drying agent greatly facilitates clinical operation and shortens the preoperative preparation time.

The present invention relates to a lipid nanoparticle comprising: (a) an ionizable lipid; (b) a helper lipid; (c) a sterol; and (d) a PEGylated lipid, wherein: (i) the PEGylated lipid comprises a hydrocarbon chain comprising more than 14 C atoms; and / or (ii) the PEGylated lipid is at a concentration of at least 3 %mol.

The present invention relates to a composition comprising: a first pegylated tetanus neurotoxin (PEG-TeNT) and a second tetanus neurotoxin (TeNT), the PEG-TeNT comprising a tetanus neurotoxin (TeNT) conjugated to polyethylene glycol (PEG). The invention also relates to a variety of PEG-TeNT. The invention also relates to a method for treating hypotension by using the composition or the various PEG-TeNTs, and a kit comprising the composition or the various PEG-TeNTs. In one embodiment, the hypotension is an obstructive sleep apnea.

The invention relates to lipid nanoparticles for delivering FSHR-siRNA as well as a preparation method and application of the lipid nanoparticles, and belongs to the technical field of pharmaceutical preparations. The preparation method comprises the following steps: S1, dissolving ionizable cationic lipid, auxiliary lipid, cholesterol and pegylated lipid in an organic solvent to obtain an oil phase; the method comprises the following steps: dissolving FSHR-siRNA in a first buffer solution to obtain a water phase; and S2, mixing the oil phase and the water phase by adopting a microfluidic technology, diluting with a second buffer solution, and removing the organic solvent to obtain the lipid nanoparticles for delivering the FSHR-siRNA. The lipid nanoparticle has excellent transfection efficiency and relatively high stability, and by virtue of delivery of the FSHR-siRNA by virtue of the lipid nanoparticle, a series of difficulties faced by effective transcription and translation of the FSHR-siRNA in vivo can be effectively solved.

The present application provides a kind of polyglycolated ropivacaine derivative, with the structure of PEG-D p The PEG polyglycolated ropivacaine derivative described is significantly longer in analgesic duration compared to ropivacaine hydrochloride, and the analgesic effect of the double-end polyglycolated ropivacaine derivative is better than that of the four-arm or eight-arm polyglycolated ropivacaine derivative.

A composition includes a compound of Formula 1, a solvate thereof, or a salt thereof. A method for treating an inflammatory disease includes administering the compound to a subject in need thereof. The compound of Formula 1 can protect cells and reduce inflammation by removing reactive oxygen species and suppressing inflammatory cytokines in a non-toxic manner.